Discovery Unit News Today

Collaboration combines Engitix’s unique human extracellular matrix (ECM) platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisationAgreement with Takeda for the discovery and development of novel therapeutics for inflammatory bowel disease (IBD) builds on existing colla...

Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease - read this article along with other careers information, tips and advice on BioSpace